For example, a study evaluating T-DM1 in combination with docetaxel (with or without pertuzumab) for HER2-positive breast cancer demonstrated dose-limiting toxicities (DLTs) and grade ≥ 3 adverse events in approximately 80% patients with metastatic breast cancer [18]. Here, ERBB2 is linked to breast carcinoma.